Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement.
Boguszewski MCS, Boguszewski CL, Chemaitilly W, Cohen LE, Gebauer J, Higham C, Hoffman AR, Polak M, Yuen KCJ, Alos N, Antal Z, Bidlingmaier M, Biller BMK, Brabant G, Choong CSY, Cianfarani S, Clayton PE, Coutant R, Cardoso-Demartini AA, Fernandez A, Grimberg A, Guðmundsson K, Guevara-Aguirre J, Ho KKY, Horikawa R, Isidori AM, Jørgensen JOL, Kamenicky P, Karavitaki N, Kopchick JJ, Lodish M, Luo X, McCormack AI, Meacham L, Melmed S, Mostoufi Moab S, Müller HL, Neggers SJCMM, Aguiar Oliveira MH, Ozono K, Pennisi PA, Popovic V, Radovick S, Savendahl L, Touraine P, van Santen HM, Johannsson G.
Boguszewski MCS, et al. Among authors: bidlingmaier m.
Eur J Endocrinol. 2022 Apr 21;186(6):P35-P52. doi: 10.1530/EJE-21-1186.
Eur J Endocrinol. 2022.
PMID: 35319491
Free PMC article.
Review.